Volume 9 Issue 2, June 2015

Sanofi Pasteur, the vaccines division of Sanofi, is seeking partners with a common drive for excellence who will share the company’s pursuit of innovation.

HitGen’s advanced encoded library technology, including its recently released nonexclusive-use OpenDEL and macrocycle libraries, affords exciting opportunities for those involved in early-stage drug discovery around challenging targets.

AnGes MG is poised to create a new drug market with Collategene.

Already firmly established as one of the preeminent early-stage biomedical clusters and innovation communities in China, BioBAY is poised to become a leading force in diagnostics and related areas.

For over 15 years, GENEWIZ has accelerated life science research and discovery by providing researchers with high-quality, cost-effective, time-saving and innovative genomics solutions.

QIAGEN (Suzhou) Translational Medicine Co. (TMC) Ltd. is the first diagnostic R&D company focused on translational science in China. The company provides complete solutions for precision medicine through translational science.

Point of care testing (POCT) enables rapid diagnostic tests to be performed while a patient is at a PoC facility, without the need for complex equipment or a wait of hours to days for reports from outside labs.

With the help of BioCentury, Biopharma Dealmakers is provides an update on the deal-trends analysis in the antibody field.

Vaccinex’s proprietary full-length human antibody discovery engine, ActivMAb, integrates selection and manufacturing in the same mammalian host to streamline development.

Invenra’s new proprietary platform, which combines cell-free protein expression with extreme miniaturization, enables the direct phenotypic interrogation of large numbers of full-length antibodies and their derivatives, empowering the discovery of next-generation biologics.

Crescendo Biologics is poised to significantly impact the world of antibody therapeutics with the enormous potential of its Humabody technology and its product-discovery and engineering capabilities.

AnaptysBio’s monoclonal-antibody approach—currently in preclinical development—may provide a therapeutic option for generalized pustular psoriasis.

Celonic is a private Swiss biotech company specializing in the production of recombinant proteins in mammalian cell systems for use in any stage of drug development.

MicroVue Pan-Specific C3 Reagent Kit – A novel approach to fill the gap of animal-specific Complement ELISAs

To all antibody hunters: “Have you screened enough?”

Today, academic-industrial partnerships are part of an integrated development strategy for any of the world’s top ten pharmaceutical companies and a growing number of academic institutions.

Forging new ground—and new collaborations—in translating research into cancer therapies.

MD Anderson Cancer Center is one of the largest and most respected centers of its kind in the world, with a wealth of resources and expertise to offer biopharmaceutical companies aiming to catapult next-generation cancer therapies into the clinic.

Close collaboration between A*STAR’s D3 (Drug Discovery and Development) unit and Experimental Therapeutics Centre accelerates the progress of research on drug candidates from the preclinical stage to proof-of-concept studies in humans.

CHLA is engaging with internal and external partners to develop healthcare solutions that deliver lifelong benefits for conditions that originate in childhood.

Three collaborative platforms—a Center for Innovation (COI), a tripartite industry-academia group (DUCR, TLO and UTEC) and the Translational Research Initiative (TRI)—showcase the University of Tokyo’s commitment to the development and commercialization of new healthcare technologies.

Since 2006, BioWin, the health cluster of the Belgian region of Wallonia, has powered a renaissance of technological and scientific excellence in cell therapy and regenerative medicine.

The French Institute of Health and Medical Research (Inserm) has developed a unique model for technology transfer through Inserm Transfert, its subsidiary in charge of de-risking innovative preclinical projects and bridging discovery and clinical research.

The Universidad Nacional Autónoma de México’s technology transfer office—Coordinación de Innovación y Desarrollo—provides a one-stop shop for innovation emerging from Mexico.

With a distinguished history in the medical sciences and engineering, the University of Southampton continues to lead as a partner of choice in immunology and bioengineering.

Universitat Autònoma de Barcelona

Regenerative medicine and advanced technologies make up a diverse group of therapeutics. As curative strategies for treating disease, they have the potential to alter the standard of care for many indications. With associated risks now tempered, investors and big pharma are showing interest.

Regenerative medicine company International Stem Cell Corporation (ISCO) leads the way in developing new treatments for Parkinson’s disease and other clinical conditions using a unique stem cell approach.

With its unique LentiVector platform and expanding state-of-the-art manufacturing facilities, Oxford BioMedica has established itself as the partner of choice for companies developing advanced therapy medicinal products.

Histide’s Cell Recoding Molecules provide a diverse source of nonmutagenic extracellular therapeutic agents for tissue regeneration and disease healing.

apceth’s innovative modular proprietary technology provides versatility and endless possibilities for generating specific targeted cell-based therapies.

Sphere Fluidics’ picodroplet technology provides a high-throughput mass spectrometry solution to help accelerate synthetic biology research.

Benitec Biopharma’s DNA-directed RNA interference platform can generate single-application therapies to silence defective genes in a wide range of diseases whilst overcoming many of the limitations of short interfering RNA.

Cell-culture and cell-isolation company STEMCELL Technologies is seeking biotech partners to develop its CAR T cell products for clinical use.

Eyevensys is pioneering mini-invasive electroporation to express therapeutic proteins in situ to treat major ophthalmic diseases.

Cellect Biomed has developed a stem cell selection process it hopes will optimize clinical and research applications of stem cells and provide a boon to the stem cell industry. The company’s ultimate goal is to make stem cell transplantation a safer and more effective medical procedure.

With promising early-phase data in hand, BrainStorm Cell Therapeutics is now putting its stem cell treatment for amyotrophic lateral sclerosis (ALS) through the rigors of phase 2 testing.